CORAL SPRINGS, Florida, May 9, 2014 /PRNewswire/ --
Marijuana & Cannabinoid Based Medicine industry continues to grow as companies forge ahead searching for new research and development, as well as expansion, opportunities: New Colombia Resources, Inc. (OTC: NEWC), GW Pharmaceuticals plc (NASDAQ: GWPH), Hemp, Inc. (OTC: HEMP), Nuvilex, Inc. (OTC: NVLX) and Tranzbyte Corporation (OTC: ERBB)
New Colombia Resources, Inc. (OTCQB: NEWC), a U.S. company with coal and other resource assets in Colombia, is pleased to announce an agreement of collaboration with the Phoenix Tears Foundation for the research and development of a cannabis based medicine to treat skin cancer in Colombia. Dr. Janet Sweeney PhD and Corrie Yelland founders of the Phoenix Tears Foundation have been helping cancer patients with Cannabis based medicines while documenting their research since 2006. New Colombia Resources is also in discussions with Cannabis Science, Inc. (OTCQB: CBIS) to oversee clinical trials in Colombia.
The Phoenix Tears Foundation is the namesake of the world famous Phoenix Tears Oil, an extremely potent and sedative cannabis resin with 75-90% THC. They have documented this medicine curing several forms of cancer. The Phoenix Tears Foundation works with Patients Out of Time, a charity dedicated to educating health care professionals and the public about the therapeutic use of cannabis. This organization treats cancer patients in critical need. Most of these patients have no other alternative and have been told by their doctors there is nothing they can do. Within weeks of using the medicine they show remarkable improvement. In many cases the skin cancer is gone within months of using the oil. For more information and testimonials please visit http://www.phoenixtearsfoundation.com
To read the full press release, please click here: http://www.fnmprofiles.com/profiles-newc.html
New Colombia Resources and their scientific advisor, Dr. Robert Melamede PhD, President of Cannabis Science, Inc. (CBIS) are reviewing a proposal from a consulting firm establishing the procedures to begin clinical trials in Colombia. The Company has a clear path of the steps needed to gain an INVIMA approved product. The Company believes the data produced by clinical trials in Colombia can be used to support an FDA IND (Investigative New Drug) application.
GW Pharmaceuticals plc (NASDAQ: GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2014 Health Care Conference in Las Vegas, NV on Tuesday, 13 May, 2014 at 4:20 p.m. PT (1:20 p.m. ET). The conference will be held at the Encore at Wynn Las Vegas. A live audio webcast of the presentation will be available through GW's corporate website in the investor relations section from the investor's calendar of events page at http://www.gwpharm.com. A replay will be available soon after the live presentation.
Hemp, Inc.'s (OTC Pink: HEMP) wholly owned subsidiary, The Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC), recently announced that it has signed a consultant agreement with Cloud Medical Doctor Software Corporation (Cloud-MD) (NSCT), a leading provider of "Cloud Based" Medical Software solutions and a provider of Digital Electronic Encryption Security solutions (CipherShop) in order to enhance the Industrial Hemp and Medical Marijuana sector's security and inventory management with a new level of professional encryption. The collaboration will allow Cloud-MD to receive and utilize industry-specific consulting services in the area of sales and marketing strategy, press releases, public company venues and general business guidance as the company expands its reach beyond traditional medical software clients into the Industrial Hemp and Medical Marijuana industries. Both Hemp, Inc. and Cloud-MD executives believe Cloud-MD's integrated and interoperable suite of software will become the "Gold Standard" for the industry's need for better cyber security and inventory management.
Nuvilex, Inc. (OTCQB: NVLX) recently announced that its advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA approved pancreatic cancer drug Gemzar®, then it was NASDAQ's Celgene and its recently FDA approved treatment of Abraxane®plus gemcitabine, and now the latest treatment that Nuvilex's Cell-in-a-Box® combined with the anticancer drug ifosfamide outperforms is NASDAQ-listed Merrimack Pharmaceuticals and its treatment, the combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin. Between these three biopharmaceutical firms, each has FDA approval or is about to face the FDA seeking approval for an advanced pancreatic cancer treatment. They also represent 3 separate treatments that Nuvilex's Cell-in-a-Box®/ifosfamide combination has produced better data than in two successfully completed Phase I/II clinical trials.
Tranzbyte Corporation (OTC Pink: ERBB) through the American Green Division together with USEI (OTC: USEI) have signed an agreement to joint venture a grow and dispensary project in the metropolitan Denver region. The project will incorporate USEI's "lighting," American Green's Jurassic water system, and a trial of a top cannabis nutrient product. In addition, the state-approved facility has a recreational dispensary license to be operated by an experienced professional in the business, well known in the market. "It's one thing to talk about our innovative products and quite another thing to ask others to believe in them. This new venture with USEI puts our own skin in the game. We know American Green products work. We also know that USEI's products work. Our combined commitment to improving grow technology is specifically focused on helping to improve the market sector for everyone," says Tranzbyte COO Stephen Shearin.
FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details. Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook: http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG was not compensated for this New Colombia Resources, Inc. news coverage but expects to be compensated in the future which will be fully disclosed at that time..
FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.
SOURCE FN Media Group, LLC